XML 69 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenues
 12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
Product Revenues
Revenues by product are summarized as follows:
 
For the Years Ended December 31,
 
2019
 
2018
 
2017
(In millions)
United
States
 
Rest of
World
 
Total
 
United
States
 
Rest of
World
 
Total
 
United
States
 
Rest of
World
 
Total
Multiple Sclerosis (MS):
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TECFIDERA
$
3,306.5

 
$
1,126.2

 
$
4,432.7

 
$
3,253.2

 
$
1,020.9

 
$
4,274.1

 
$
3,294.0

 
$
920.0

 
$
4,214.0

Interferon*
1,426.6

 
675.2

 
2,101.8

 
1,668.3

 
694.7

 
2,363.0

 
1,889.1

 
756.7

 
2,645.8

TYSABRI
1,041.8

 
850.4

 
1,892.2

 
1,025.0

 
839.0

 
1,864.0

 
1,113.8

 
859.3

 
1,973.1

VUMERITY
5.5

 
—

 
5.5

 
—

 
—

 
—

 
—

 
—

 
—

FAMPYRA
—

 
97.1

 
97.1

 
—

 
92.7

 
92.7

 
—

 
91.6

 
91.6

ZINBRYTA
—

 
—

 
—

 
—

 
1.4

 
1.4

 
—

 
52.7

 
52.7

Subtotal: MS Product Revenues
5,780.4

 
2,748.9

 
8,529.3

 
5,946.5

 
2,648.7

 
8,595.2

 
6,296.9

 
2,680.3

 
8,977.2

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spinal Muscular Atrophy:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SPINRAZA
933.4

 
1,163.6

 
2,097.0

 
854.0

 
870.2

 
1,724.2

 
657.0

 
226.7

 
883.7

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biosimilars:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BENEPALI
—

 
486.2

 
486.2

 
—

 
485.2

 
485.2

 
—

 
370.8

 
370.8

IMRALDI
—

 
184.0

 
184.0

 
—

 
16.7

 
16.7

 
—

 
—

 
—

FLIXABI
—

 
68.1

 
68.1

 
—

 
43.2

 
43.2

 
—

 
9.0

 
9.0

Subtotal: Biosimilar product revenues
—

 
738.3

 
738.3

 
—

 
545.1

 
545.1

 
—

 
379.8

 
379.8

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FUMADERM
—

 
15.2

 
15.2

 
—

 
22.3

 
22.3

 
—

 
39.6

 
39.6

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hemophilia:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ELOCTATE
—

 
—

 
—

 
—

 
—

 
—

 
42.2

 
6.2

 
48.4

ALPROLIX
—

 
—

 
—

 
—

 
—

 
—

 
21.0

 
5.0

 
26.0

Subtotal: Hemophilia product revenues
—

 
—

 
—

 
—

 
—

 
—

 
63.2

 
11.2

 
74.4

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total product revenues
$
6,713.8

 
$
4,666.0

 
$
11,379.8

 
$
6,800.5

 
$
4,086.3

 
$
10,886.8

 
$
7,017.1

 
$
3,337.6

 
$
10,354.7

*Interferon includes AVONEX and PLEGRIDY.
We recognized revenues from two wholesalers accounting for 30% and 17% of gross product revenues in 2019, 32% and 18% of gross product revenues in 2018 and 34% and 21% of gross product revenues in 2017, respectively.
As of December 31, 2019, two wholesale distributors individually accounted for approximately 24.1% and 13.9% of net accounts receivable associated with our product sales, as compared to 27.7% and 15.6% as of December 31, 2018, respectively.
An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions)
Discounts
 
Contractual
Adjustments
 
Returns
 
Total
2019
 
 
 
 
 
 
 
Beginning balance
$
127.8

 
$
888.8

 
$
34.7

 
$
1,051.3

Current provisions relating to sales in current year
666.2

 
3,011.5

 
20.9

 
3,698.6

Adjustments relating to prior years
0.3

 
(54.1
)
 
5.5

 
(48.3
)
Payments/returns relating to sales in current year
(535.5
)
 
(2,242.9
)
 
(0.2
)
 
(2,778.6
)
Payments/returns relating to sales in prior years
(127.7
)
 
(576.0
)
 
(20.4
)
 
(724.1
)
Ending balance
$
131.1

 
$
1,027.3

 
$
40.5

 
$
1,198.9


(In millions)
Discounts
 
Contractual
Adjustments
 
Returns
 
Total
2018
 
 
 
 
 
 
 
Beginning balance
$
109.6

 
$
606.0

 
$
46.0

 
$
761.6

Current provisions relating to sales in current year
679.3

 
2,686.7

 
23.1

 
3,389.1

Adjustments relating to prior years
(0.3
)
 
(10.0
)
 
(1.8
)
 
(12.1
)
Payments/returns relating to sales in current year
(551.7
)
 
(1,887.6
)
 
(1.1
)
 
(2,440.4
)
Payments/returns relating to sales in prior years
(109.1
)
 
(506.3
)
 
(31.5
)
 
(646.9
)
Ending balance
$
127.8

 
$
888.8

 
$
34.7

 
$
1,051.3

(In millions)
Discounts
 
Contractual
Adjustments
 
Returns
 
Total
2017
 
 
 
 
 
 
 
Beginning balance
$
71.6

 
$
482.7

 
$
51.2

 
$
605.5

Current provisions relating to sales in current year
583.0

 
2,307.4

 
26.9

 
2,917.3

Adjustments relating to prior years
(0.1
)
 
15.0

 
(8.9
)
 
6.0

Payments/returns relating to sales in current year
(475.8
)
 
(1,756.9
)
 
(0.1
)
 
(2,232.8
)
Payments/returns relating to sales in prior years
(69.1
)
 
(442.2
)
 
(23.1
)
 
(534.4
)
Ending balance
$
109.6

 
$
606.0

 
$
46.0

 
$
761.6


The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:
 
As of December 31,
(In millions)
2019
 
2018
Reduction of accounts receivable
$
197.8

 
$
176.6

Component of accrued expenses and other
1,001.1

 
874.7

Total revenue-related reserves
$
1,198.9

 
$
1,051.3


Revenues from Anti-CD20 Therapeutic Programs
Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
 
For the Years Ended December 31,
(In millions)
2019
 
2018
 
2017
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses
$
1,542.4

 
$
1,431.9

 
$
1,316.4

Other revenues from anti-CD20 therapeutic programs
748.0

 
548.3

 
242.8

Total revenues from anti-CD20 therapeutic programs
$
2,290.4

 
$
1,980.2

 
$
1,559.2


Approximately 16%, 15% and 13% of our total revenues in 2019, 2018 and 2017, respectively, are derived from our collaboration arrangements with Genentech. For additional information on our collaboration arrangements with Genentech, please read Note 18, Collaborative and Other Relationships, to these consolidated financial statements.
Other Revenues
Other revenues are summarized as follows:
 
For the Years Ended December 31,
(In millions)
2019
 
2018
 
2017
Revenues from collaborative and other relationships:
 
 
 
 
 
(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.
$
—

 
$
(8.6
)
 
$
(16.9
)
Revenues earned under our technical development services and manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis
106.2

 
96.4

 
42.7

Revenues earned under manufacturing services agreement on shipments of ELOCTA and ALPROLIX to Swedish Orphan Biovitrum AB (Sobi) and royalties from Sobi on sales of ELOCTA and ALPROLIX
—

 
—

 
10.7

Other royalty and corporate revenues:
 
 
 
 
 
Royalty
17.0

 
38.7

 
69.8

Other corporate
584.5

 
459.4

 
253.7

Total other revenues
$
707.7

 
$
585.9

 
$
360.0


Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic customers, including Bioverativ Inc. (Bioverativ). During the years ended December 31, 2019, 2018 and 2017, we recognized $383.2 million, $206.7 million and $64.8 million, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.
During the third quarter of 2019 we amended our agreement with a contract manufacturing customer. Under the amended agreement, we will license certain of our manufacturing-related intellectual property to the customer. We will be eligible to receive $500.0 million in a series of three payments. The first payment is due upon a regulatory achievement related to the customer's product manufactured using our manufacturing-related intellectual property, with subsequent payments payable upon the first and second anniversaries of the regulatory achievement. We expect the regulatory achievement to occur in 2020. If we earn this payment, we expect to allocate the consideration between the license for the manufacturing-related intellectual property and the manufacturing product supply services.
For additional information on our collaboration arrangements with AbbVie Inc. (AbbVie) and Samsung Bioepis, please read Note 18, Collaborative and Other Relationships, to these consolidated financial statements.